<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363659</url>
  </required_header>
  <id_info>
    <org_study_id>17.56</org_study_id>
    <nct_id>NCT03363659</nct_id>
  </id_info>
  <brief_title>Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme</brief_title>
  <official_title>A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate When Added to Standard Temozolomide Treatment in Patients With Newly Diagnosed Resected Unmethylated Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurora Health Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurora Health Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of Disulfiram antitumor effects suggested in preclinical studies is MGMT&#xD;
      (methyl-guanine-methyl-transferase) inhibition. Disulfiram MGMT inhibitory effect is enhanced&#xD;
      by addition of Copper. This study evaluates the impact of DSF + Cu combination when added to&#xD;
      standard Temozolomide in the treatment of unmethylated GBM patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glioblastoma is the most common malignant primary brain tumor and one of the most devastating&#xD;
      cancers. The current standard of care for glioblastoma includes maximal safe resection&#xD;
      followed by radiotherapy and temozolomide, which results in a median progression-free&#xD;
      survival of less than 7 months, and median overall survival (OS) of less than 15 months.&#xD;
      Moreover, patients with unmethylated glioblastoma respond poorly to this current standard&#xD;
      treatment. This clinical trial evaluates the potential role of continuous, upfront use of&#xD;
      Disulfiram in combination with Copper gluconate in enhancing temozolomide effect in the&#xD;
      treatment of unmethylated GBM patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 28, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 and 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>1 year</time_frame>
    <description>Edmonton Symptom Assessment System - Revised (ESAS-r) questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>DSF-Cu with temozolomide and radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Disulfiram (DSF; oral) / copper gluconate (Cu; oral) dosed at 125 mg / 2 mg, twice daily. Temozolomide will be administered following the standard Stupp protocol at a dose of 75 mg/m2 for 42 days with concurrent radiation therapy. Temozolomide maintenance dose will be 150 mg/m2 once daily on Days 1-5 of every 28-day cycle while DSF-Cu is continued twice daily, as tolerated, for the duration of the Temozolomide adjuvant treatment. Patients demonstrating continued benefit from the adjuvant temozolomide after 6 cycles can continue treatment to a maximum of 12 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Disulfiram</intervention_name>
    <description>Disulfiram is taken orally, twice daily.</description>
    <arm_group_label>DSF-Cu with temozolomide and radiation</arm_group_label>
    <other_name>Antabuse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Copper gluconate</intervention_name>
    <description>Copper gluconate is taken orally, twice daily</description>
    <arm_group_label>DSF-Cu with temozolomide and radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Temozolomide is taken once daily</description>
    <arm_group_label>DSF-Cu with temozolomide and radiation</arm_group_label>
    <other_name>Temodar, Temodal, Temcad</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Diagnosis of histologically confirmed glioblastoma (WHO grade IV). Subjects with an&#xD;
             original histologic diagnosis of low grade glioma or anaplastic glioma (WHO grade II&#xD;
             or III) are eligible if a subsequent histological diagnosis of glioblastoma is made&#xD;
&#xD;
          -  Patients whose tumor is determined to be unmethylated&#xD;
&#xD;
          -  Patients with incomplete resection as determined by residual, measurable gadolinium or&#xD;
             contrast-enhancing lesion or lesions&#xD;
&#xD;
          -  Recent resection of glioblastoma within 4 weeks of study entry. Patients who have only&#xD;
             had a tumor biopsy and who are considered unresectable are eligible (but based on the&#xD;
             study accrual this subset of patients with unresectable tumor may be considered for&#xD;
             separate analysis)&#xD;
&#xD;
          -  ECOG PS of ≤ 2 (see appendix A)&#xD;
&#xD;
          -  Willing to remain abstinent from consuming alcohol while on DSF&#xD;
&#xD;
          -  No prior radiation or chemotherapy&#xD;
&#xD;
          -  Meets the following laboratory criteria:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500/mcL&#xD;
&#xD;
               -  Platelets ≥ 100,000/mcL&#xD;
&#xD;
               -  Hemoglobin &gt; 10.0 g/dL (transfusion and/or ESA allowed)&#xD;
&#xD;
               -  Total bilirubin and alkaline phosphatase ≤ 2x institutional upper limit of normal&#xD;
                  (ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 3 x ULN&#xD;
&#xD;
               -  Blood urea nitrogen (BUN) and creatinine &lt; 1.5 x ULN&#xD;
&#xD;
          -  Able to take oral medication&#xD;
&#xD;
          -  Able to understand and willing to sign an institutional review board (IRB)-approved&#xD;
             written informed consent document (legally authorized representative permitted)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radiographic evidence of leptomeningeal dissemination, extensive intraparenchymal&#xD;
             dissemination, infratentorial tumor, or metastatic disease to sites remote from the&#xD;
             supratentorial brain&#xD;
&#xD;
          -  Enrolled in another clinical trial testing a novel therapy or drug&#xD;
&#xD;
          -  Received prior radiation therapy or chemotherapy for glioblastoma&#xD;
&#xD;
          -  History of allergic reaction/hypersensitivity to DSF (without alcohol) or copper.&#xD;
&#xD;
          -  Treatment with the following medications that may interfere with metabolism of DSF:&#xD;
             warfarin (unless otherwise chosen by the study PI who will actively adjust Coumadin&#xD;
             dose to consistently maintain a safe, therapeutic INR &lt; 3), theophylline,&#xD;
             amitriptyline, isoniazid, metronidazole, phenytoin, phenobarbital, chlorzoxazone,&#xD;
             halothane, imipramine, chlordiazepoxide, diazepam. (Note: lorazepam and oxazepam are&#xD;
             not affected by the P450 system and are not contraindicated with DSF).&#xD;
&#xD;
          -  Active severe hepatic or renal disease&#xD;
&#xD;
          -  Grade 2 or higher peripheral neuropathy or ataxia per NCI CTCAE version 4.0 (2009)&#xD;
&#xD;
          -  History of idiopathic seizure disorder schizophrenia, or psychosis unrelated to&#xD;
             glioblastoma, corticosteroid, or anti-epileptic medications&#xD;
&#xD;
          -  History of Wilson's or Gilbert's disease&#xD;
&#xD;
          -  Current excessive use of alcohol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asadullah Khan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aurora Health Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aurora Health Care, Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Glioblastoma Multiforme</keyword>
  <keyword>Anaplastic Glioma</keyword>
  <keyword>Unmethylated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Copper</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Disulfiram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

